Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 90 Show results per page	View Search Criteria \| Help With Results


1.		Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 to 85				Other				20050113 NCT00243685


2.		Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				EFC6125 EudraCT : 2005-005026-31, AVE0005A /3001, NCT00327444


3.		Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				ABA-01 AGO Study Code: AGO-OVAR 10, EUDRACT No: 2006-0062801-30, NCT00418574


4.		Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Biomarker/Laboratory analysis, Treatment				Active				Not specified				Other				WIRB 20060042 NCT00443196

Last Modified: 10/24/2008 First Published: 4/7/2005


5.		Phase III Randomized Study of Paclitaxel Versus Polyglutamate Paclitaxel as Consolidation/Maintenance Therapy Versus No Further Anticancer Therapy Until Disease Progression in Patients With Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Not specified				NCI				GOG-0212 GOG-0212, NCT00108745

Last Modified: 10/24/2008 First Published: 11/25/2005


6.		Phase III Randomized Study of Carboplatin and Paclitaxel Versus Carboplatin, Paclitaxel, and Concurrent Bevacizumab With Versus Without Extended Bevacizumab in Patients With Stage III or IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				GOG-0218 GOG-0218, NCT00262847


7.		OVATURE (OVArian TUmor REsponse) Study: A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Over 18				Pharmaceutical / Industry				NV06-0039 NCT00382811


8.		Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				KTN32313R NCT00477282

Last Modified: 10/21/2008 First Published: 10/25/2004


9.		Phase I/II Study of Pentostatin and Donor Lymphocyte Infusion in Preventing Graft Rejection in Cancer Patients With Low or Falling Donor T-Cell Chimerism After Nonmyeloablative Allogeneic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Under 75				NCI, Pharmaceutical / Industry				FHCRC-1825.00 5605, SUPERGEN-FHCRC-1825.00, NCT00096161

Last Modified: 12/21/2007 First Published: 9/9/2005


10.		Phase I/II Study of Ixabepilone and Pegylated Doxorubicin HCl Lipsome in Women With Previously Treated Advanced Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer or Metastatic Breast Cancer (Phase I Closed to Accrual as of 12/6/07)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				AECM-0504007857 NCI-7229, 7229, NCT00182767

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute